Overview

A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of A4250 after single or multiple oral doses in healthy subjects. In addition, will evaluate A4250 in combination with cholestyramine.
Phase:
Phase 1
Details
Lead Sponsor:
Albireo
Treatments:
Cholestyramine Resin